Baseline characteristics
| Variable . | 8/8 MUD . | MSD . | Haplo . | 7/8 MMUD . |
|---|---|---|---|---|
| Total, N = 610 | 371 | 123 | 87 | 29 |
| Patient age, years, n (%) | ||||
| 65-69 | 205 (55.3) | 76 (61.8) | 56 (64.4) | 18 (62.1) |
| 70-74 | 135 (36.4) | 40 (32.5) | 26 (29.9) | 9 (31.0) |
| ≥75 | 31 (8.4) | 7 (5.7) | 5 (5.7) | 2 (6.9) |
| Median (IQR) | 69 (67-72) | 69 (66.5-70.5) | 68 (67-70) | 68 (66-71) |
| Donor age, years, n (%) | ||||
| <30 | 212 (57.1) | 0 (0.0) | 7 (8.0) | 15 (51.7) |
| 30-50 | 139 (37.5) | 1 (0.8) | 69 (79.3) | 13 (44.8) |
| >50 | 20 (5.4) | 122 (99.2) | 11 (12.6) | 1 (3.4) |
| Median (IQR) | 29 (35-36) | 65 (61-68) | 40 (34-44) | 30 (28-40) |
| Patient sex, n (%) | ||||
| Male | 248 (66.8) | 67 (54.5) | 66 (75.9) | 12 (41.4) |
| Female | 123 (33.2) | 56 (45.5) | 21 (24.1) | 17 (58.6) |
| Disease, n (%) | ||||
| AML/MDS | 299 (80.6) | 100 (81.3) | 70 (80.5) | 24 (82.8) |
| ALL | 3 (0.8) | 2 (1.6) | 0 (0.0) | 0 (0.0) |
| Other∗ | 69 (18.6) | 21 (17.1) | 17 (19.5) | 5 (17.2) |
| DRI, n (%) | ||||
| Low | 10 (2.7) | 1 (0.8) | 2 (2.3) | 0 (0.0) |
| Intermediate | 278 (74.9) | 93 (75.6) | 60 (69.0) | 18 (62.1) |
| High | 75 (20.2) | 27 (22.0) | 25 (28.7) | 10 (34.5) |
| Very high | 8 (2.2) | 2 (1.6) | 0 (0.0) | 1 (3.4) |
| Conditioning, n (%) | ||||
| MAC | 228 (61.5) | 82 (66.7) | 46 (52.9) | 17 (58.6) |
| RIC/NMA | 143 (38.5) | 41 (33.3) | 41 (47.1) | 12 (41.4) |
| Graft type, n (%) | ||||
| BM | 42 (11.3) | 0 (0.0) | 52 (59.8) | 6 (20.7) |
| PBPC | 329 (88.7) | 123 (100.0) | 35 (40.2) | 23 (79.3) |
| HCT-CI, n (%) | ||||
| 0 | 61 (16.4) | 19 (15.4) | 11 (12.6) | 10 (34.5) |
| 1-2 | 110 (29.6) | 35 (28.5) | 22 (25.3) | 7 (24.1) |
| ≥3 | 200 (53.9) | 69 (56.1) | 54 (62.1) | 12 (41.4) |
| D/R CMV, n (%) | ||||
| Neg/Neg | 87 (23.5) | 24 (19.5) | 16 (18.4) | 4 (13.8) |
| Neg/Pos | 160 (43.1) | 22 (17.9) | 26 (29.9) | 9 (31.0) |
| Pos/Neg | 46 (12.4) | 12 (9.8) | 11 (12.6) | 5 (17.2) |
| Pos/Pos | 78 (21.0) | 65 (52.8) | 34 (39.1) | 11 (37.9) |
| D/R sex mismatch, n (%) | ||||
| Female-to-male | 72 (19.4) | 35 (28.5) | 16 (18.4) | 3 (10.3) |
| Not female-to-male | 299 (80.6) | 88 (71.5) | 71 (81.6) | 26 (89.7) |
| KPS, n (%) | ||||
| ≥90 | 155 (41.8) | 49 (39.8) | 34 (39.1) | 10 (34.5) |
| <90 | 169 (45.6) | 56 (45.5) | 35 (40.2) | 11 (37.9) |
| Missing | 47 (12.7) | 18 (14.6) | 18 (20.7) | 8 (27.6) |
| Year of HSCT, n (%) | ||||
| <2022 | 176 (47.4) | 67 (54.5) | 48 (55.2) | 10 (34.5) |
| ≥2022 | 195 (52.6) | 56 (45.5) | 39 (44.8) | 19 (65.5) |
| Time to HSCT, months, n (%) | ||||
| <6 | 123 (33.2) | 52 (42.3) | 24 (27.6) | 8 (27.6) |
| 6-12 | 110 (29.6) | 33 (26.8) | 23 (26.4) | 11 (37.9) |
| >12 | 138 (37.2) | 38 (30.9) | 40 (46.0) | 10 (34.5) |
| Race, n (%) | ||||
| White | 345 (93.0) | 100 (81.3) | 65 (74.7) | 25 (86.2) |
| Other | 24 (6.5) | 21 (17.1) | 22 (25.3) | 4 (13.8) |
| Missing | 2 (0.5) | 2 (1.6) | 0 (0.0) | 0 (0.0) |
| Follow-up, median (IQR), mo | 23.80 (12.40-44.20) | 26.10 (13.30-47.10) | 25.40 (8.87-50.00) | 13.10 (4.89-22.30) |
| Variable . | 8/8 MUD . | MSD . | Haplo . | 7/8 MMUD . |
|---|---|---|---|---|
| Total, N = 610 | 371 | 123 | 87 | 29 |
| Patient age, years, n (%) | ||||
| 65-69 | 205 (55.3) | 76 (61.8) | 56 (64.4) | 18 (62.1) |
| 70-74 | 135 (36.4) | 40 (32.5) | 26 (29.9) | 9 (31.0) |
| ≥75 | 31 (8.4) | 7 (5.7) | 5 (5.7) | 2 (6.9) |
| Median (IQR) | 69 (67-72) | 69 (66.5-70.5) | 68 (67-70) | 68 (66-71) |
| Donor age, years, n (%) | ||||
| <30 | 212 (57.1) | 0 (0.0) | 7 (8.0) | 15 (51.7) |
| 30-50 | 139 (37.5) | 1 (0.8) | 69 (79.3) | 13 (44.8) |
| >50 | 20 (5.4) | 122 (99.2) | 11 (12.6) | 1 (3.4) |
| Median (IQR) | 29 (35-36) | 65 (61-68) | 40 (34-44) | 30 (28-40) |
| Patient sex, n (%) | ||||
| Male | 248 (66.8) | 67 (54.5) | 66 (75.9) | 12 (41.4) |
| Female | 123 (33.2) | 56 (45.5) | 21 (24.1) | 17 (58.6) |
| Disease, n (%) | ||||
| AML/MDS | 299 (80.6) | 100 (81.3) | 70 (80.5) | 24 (82.8) |
| ALL | 3 (0.8) | 2 (1.6) | 0 (0.0) | 0 (0.0) |
| Other∗ | 69 (18.6) | 21 (17.1) | 17 (19.5) | 5 (17.2) |
| DRI, n (%) | ||||
| Low | 10 (2.7) | 1 (0.8) | 2 (2.3) | 0 (0.0) |
| Intermediate | 278 (74.9) | 93 (75.6) | 60 (69.0) | 18 (62.1) |
| High | 75 (20.2) | 27 (22.0) | 25 (28.7) | 10 (34.5) |
| Very high | 8 (2.2) | 2 (1.6) | 0 (0.0) | 1 (3.4) |
| Conditioning, n (%) | ||||
| MAC | 228 (61.5) | 82 (66.7) | 46 (52.9) | 17 (58.6) |
| RIC/NMA | 143 (38.5) | 41 (33.3) | 41 (47.1) | 12 (41.4) |
| Graft type, n (%) | ||||
| BM | 42 (11.3) | 0 (0.0) | 52 (59.8) | 6 (20.7) |
| PBPC | 329 (88.7) | 123 (100.0) | 35 (40.2) | 23 (79.3) |
| HCT-CI, n (%) | ||||
| 0 | 61 (16.4) | 19 (15.4) | 11 (12.6) | 10 (34.5) |
| 1-2 | 110 (29.6) | 35 (28.5) | 22 (25.3) | 7 (24.1) |
| ≥3 | 200 (53.9) | 69 (56.1) | 54 (62.1) | 12 (41.4) |
| D/R CMV, n (%) | ||||
| Neg/Neg | 87 (23.5) | 24 (19.5) | 16 (18.4) | 4 (13.8) |
| Neg/Pos | 160 (43.1) | 22 (17.9) | 26 (29.9) | 9 (31.0) |
| Pos/Neg | 46 (12.4) | 12 (9.8) | 11 (12.6) | 5 (17.2) |
| Pos/Pos | 78 (21.0) | 65 (52.8) | 34 (39.1) | 11 (37.9) |
| D/R sex mismatch, n (%) | ||||
| Female-to-male | 72 (19.4) | 35 (28.5) | 16 (18.4) | 3 (10.3) |
| Not female-to-male | 299 (80.6) | 88 (71.5) | 71 (81.6) | 26 (89.7) |
| KPS, n (%) | ||||
| ≥90 | 155 (41.8) | 49 (39.8) | 34 (39.1) | 10 (34.5) |
| <90 | 169 (45.6) | 56 (45.5) | 35 (40.2) | 11 (37.9) |
| Missing | 47 (12.7) | 18 (14.6) | 18 (20.7) | 8 (27.6) |
| Year of HSCT, n (%) | ||||
| <2022 | 176 (47.4) | 67 (54.5) | 48 (55.2) | 10 (34.5) |
| ≥2022 | 195 (52.6) | 56 (45.5) | 39 (44.8) | 19 (65.5) |
| Time to HSCT, months, n (%) | ||||
| <6 | 123 (33.2) | 52 (42.3) | 24 (27.6) | 8 (27.6) |
| 6-12 | 110 (29.6) | 33 (26.8) | 23 (26.4) | 11 (37.9) |
| >12 | 138 (37.2) | 38 (30.9) | 40 (46.0) | 10 (34.5) |
| Race, n (%) | ||||
| White | 345 (93.0) | 100 (81.3) | 65 (74.7) | 25 (86.2) |
| Other | 24 (6.5) | 21 (17.1) | 22 (25.3) | 4 (13.8) |
| Missing | 2 (0.5) | 2 (1.6) | 0 (0.0) | 0 (0.0) |
| Follow-up, median (IQR), mo | 23.80 (12.40-44.20) | 26.10 (13.30-47.10) | 25.40 (8.87-50.00) | 13.10 (4.89-22.30) |
AML, acute myeloid leukemia; BM, bone marrow; CMV, cytomegalovirus; DRI, disease risk index; D/R, donor/recipient; Haplo, haploidentical; HCT-CI, hematopoietic cell transplantation comorbidity index; IQR, interquartile range; KPS, Karnofsky performance status; MAC, myeloablative conditioning; Neg, negative; NMA, nonmyeloablative conditioning; PBPC, peripheral blood progenitor cells; Pos, positive; RIC, reduced-intensity conditioning.
Other includes chronic lymphoid leukemia, chronic myeloid leukemia, myeloproliferative disease, lymphoma, and multiple myeloma.